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Objectives: Patients with asthma exacerbations requiring inpatient care com-
prise a sub-group at high risk of adverse asthma-related outcomes. The quality 
of care in these individuals can thus have substantial impact on the burden of 
asthma. The purpose of this study was to provide a broad picture on the out-
comes associated with different treatment strategies after discharge from 
an asthma-related admission. MethOds: Using administrative health data 
of British Columbia, Canada (1997-2012), we created a cohort of individuals 
discharged from an episode of asthma-related hospitalization. Exposure was 
assessed in the 60 days after discharge, and was categorized as no controller 
treatment, monotherapy with inhaled corticosteroids (ICS), or combination ther-
apy with ICS plus long-acting beta agonists (LABA). Safety (re-admission), adher-
ence (proportion of days covered [PDC] with controller medications, and health 
resource use (asthma-related costs) outcomes were ascertained in the next 365 
days. Generalized propensity scores were calculated to achieve balance in the 
distribution of potential confounders across exposure groups. Results: The final 
cohort included 1,864; 848; and 954 post-discharge periods, respectively, for no 
treatment, ICS-only, and ICS+LABA groups. Asthma-related admissions were 
significantly lower in the ICS-only groups compared with no treatment group 
(RR= 0.69 [95%CI 0.55 - 0.87], P= 0.001), but were similar between the ICS+LABA and 
ICS-only groups (RR= 0.96 [95% CI 0.73 - 1.27], P= 0.787). The PDC by a controller 
medication was significantly higher in the ICS group compared with no treatment 
(difference of 8.7% [95% CI 6.8% - 10.5%], P< 0.001), as well as PDC by ICS+LABA 
compared with PDC by ICS (difference of 7.2% [95%CI 4.7% - 9.6%], P< 0.001). There 
were no differences in costs across the three groups. cOnclusiOns: Initiation 
of controller medications in the post-discharge period was associated with sig-
nificant benefits. The higher adherence to controller medication between the 
ICS+LABA compared with ICS-only group can translate to better outcomes in 
the long term.
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Objectives: To investigate smoking cessation behaviors in Japanese current smok-
ers (CS) and former smokers (FS). MethOds: An online survey of Japanese men 
and women ≥ 20 years of age who were CS or FS was conducted. CS were those who 
smoked any number of cigarettes at the time of the survey (24–27 June 2013); FS 
were those who had smoked any number of cigarettes in the past but did not con-
sider themselves smokers at the time of the survey. Clinical and socio-demographic 
characteristics (age, gender, level of education, and level of nicotine dependence 
[Fagerström Test for Nicotine Dependence]) as well as smoking and smoking ces-
sation history, were assessed through a web-based questionnaire. We set primary 
outcome measures as the number of past quit attempts and the time to relapse 
(duration of smoking abstinence). Secondary outcome measures included methods 
used to achieve smoking cessation, and reasons for wanting to quit. Results: A 
total of 1261 eligible Japanese subjects were included in the survey (CS, n = 631; FS, 
n = 630). Mean age and gender distribution were broadly similar between the groups. 
Nearly half (45.6%) of CS had never attempted to quit smoking. Of those who had 
attempted to quit smoking, one single quit attempt was the most common for both 
CS and FS (19.0 vs. 39.0%). The estimated median time to relapse was 105 days (FS 
and CS combined). Unaided smoking cessation was the most common method both 
for CS and FS (78.2 vs. 63.4%). cOnclusiOns: Our observations reveal the actual 
smoking cessation behaviors in a Japanese population, and could be combined 
with other data in economic evaluation models of smoking cessation interventions 
in Japan to identify appropriate measures to reduce the prevalence of smoking.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is associated with 
elevated levels of pulmonary and systemic inflammatory markers which may lead 
to high prevalence of inflammation-related conditions. This study examines the 
prevalence and demographic predictors of inflammation-related multimorbidity 
among Medicaid beneficiaries with COPD. MethOds: Observational retrospec-
tive cohort study using multiple years (2005-2006) of data from Medicaid Analytic 
eXtract (MAX) files of California (CA), Illinois (IL), New York (NY) and Texas (TX). 
Individuals with COPD (n = 37,151) were identified using ICD-9-CM codes for 
chronic bronchitis (491.xx), emphysema (492.xx), or unspecified chronic airway 
obstruction (496.xx). Inflammation-related multimorbidity included: cardio-vascu-
lar disease, depression, diabetes mellitus, hypertension, hyperlipidemia and mus-
culoskeletal disorders. This variable was categorized into: (i) both physical/mental 
illness (IF_PHY/MI); (ii) physical illness only (IF_PHY/no MI); (iii) mental illness 
only (IF_no PHY/ MI); (iv) NONE. Unadjusted group differences were tested using 
the chi-square statistics. Multinomial logistic regression was used to analyze the 
association between demographic predictors and inflammation-related multimor-
bidity. All analyses were conducted using SAS. Results: Overall, 78.9% of study 
population had an inflammation-related multimorbidity, of which 22.9% had IF_
we sought to determine the prevalence of PIMs for older adults in Emilia-Romagna, 
Italy, using the updated Maio criteria. We also evaluated patient and general prac-
titioner (GP) characteristics related to inappropriate prescribing. MethOds: Older 
adults (≥ 65) in 2012 were evaluated in a one-year retrospective study using adminis-
trative health care data. The 2011 Maio criteria includes 25 medications reimbursed 
by the Italian National Formulary, in the following categories in terms of severity: 
16 medications that ‘should always be avoided,’ 3 that are ‘rarely appropriate,’ and 6 
that have ‘some indications although they are often misused.’ To evaluate the extent 
of associations between patient and GP related characteristics, we used generalized 
estimating equations with an exchangeable covariance design to fit a robust logistic 
regression model. Results: A total of 865,354 older adults were in the cohort and 
28% had at least one PIM. Of the entire cohort, 8%, 10%, and 14% of individuals 
were prescribed at least one medication that ‘should always be avoided,’ ‘rarely 
appropriate,’ and has ‘some indications but are often misused,’ respectively. Older 
patients (≥ 75) and females were more likely to be exposed to PIMs. 2,923 GPs were 
identified in the region that prescribed at least one PIM, of which older (≥ 56) GPs, 
male GPs, and solo practice GPs were more likely to prescribe PIMs to their older 
patients. cOnclusiOns: The high prevalence of PIM exposure among older adults 
is a substantial issue in the region. Knowing how patient and GP characteristics 
relate to PIMs exposure may improve the design and targeting of initiatives for 
improving prescribing safety in this population.
Pih88
teSting foR ChildRen With PhaRyngitiS; imPRoving tRendS toWaRdS 
aPPRoPRiate antibiotiC uSe
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Objectives: Overuse of antibiotics in children is a growing concern in the US. 
One of the important HEDIS quality measures used to compare performance of 
health plans incorporates appropriate prescribing of antibiotics for children with 
pharyngitis. The current study examined this measure over four years to deter-
mine if physician behavior had changed over time. MethOds: Patients aged 2-18 
diagnosed with pharyngitis (ICD-9-CM 462, 463 and 034.0) on a medical claim 
(‘index’) and dispensed an antibiotic were identified in administrative claims data 
from the Truven Health MarketScan® Research databases (2008-2012). From this 
eligible population, the proportion of patients having evidence of a streptococ-
cus test in the seven-day period from three days prior to index through three 
days post-index was calculated. A higher rate represents better performance (i.e., 
appropriate testing). Rates were examined overall and by age group. Results: In 
fiscal year (FY) 2009, 68.9% of eligible patients had evidence of a streptococcus test. 
Appropriate testing rates were highest for patients aged 5-7 and 8-10 (76.1% and 
75.1%, respectively) and lowest for those aged 14-16 and 17-18 (62.0% and 59.9%, 
respectively). The rate of appropriate testing grew slightly in FY2010 to 70.2% with 
very similar age-group specific rates. In FY2011, the overall rate grew by nearly 
6% to 74.3%. Age group trends continued, with 80.3% of patients aged 5-7 and 
78.3% of patients aged 8-10 appropriately tested. In FY2012 the overall rate grew 
to 76.0%, with patients aged 5-7 and 8-10 continuing to have the highest rate of 
testing (81.1% and 80.8%, respectively) and those aged 14-16 and 17-18 the low-
est rate (71.6% and 67.0%, respectively). cOnclusiOns: The rate of appropriate 
testing for antibiotic use in children with pharyngitis increased by 10% between 
FY2009 and FY2012. While the trend is moving in the right direction, significant 
room for improvement remains.
ReSPiRatoRy-Related diSoRdeRS – Clinical outcomes Studies
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Objectives: Tiotropium is widely used in patients with chronic obstructive pul-
monary disease (COPD), and is effective in reducing the risk of COPD exacerba-
tions. However, controversies exist around its safety, especially with regard to 
cardiac arrhythmia. This study aimed to evaluate the risk of tiotropium for cardiac 
arrhythmia hospitalization. MethOds: A self-controlled case series was under-
taken using the IMS LifeLink Health Plan Claims Databases. COPD patients aged 
45 years or older and hospitalized with cardiac arrhythmia during the observation 
period, from 2008 to 2011, were included. The exposure periods were defined for 
each patient as the dispensing periods of tiotropium plus an additional following 
30 days as the wash-out period. The remaining time within the observation period 
in which patients were not using tiotropium were the unexposed periods. The inci-
dence rate ratio (IRR) of cardiac arrhythmia hospitalization was calculated by com-
paring exposed and unexposed periods using multivariable conditional Poisson 
regression. Results: A total of 86,108 COPD patients with cardiac arrhythmia hos-
pitalizations were included. Among those, 14,398 patients (16.7%) received tiotro-
pium. The average age of the cohort at the beginning of the observation period was 
72.3 ± 12.4 years. The median follow-up time was 1,216 days (inter-quartile range; 
731 – 1,461 days). The IRR of tiotropium on cardiac arrhythmia hospitalization 
was 1.18 [95% confidence interval (CI) 1.12 – 1.24]. The IRR was highest in the first 
14 days of initiation of tiotropium [IRR 1.94; 95% CI 1.71 – 2.21] and slightly 
decreased over time but remained statistically significant. cOnclusiOns: 
Tiotropium was associated with an increased risk of cardiac arrhythmia hospi-
talization. The risk is highest in the first 14 days of initiation of tiotropium and 
decreased overtime. Patients initiating tiotropium should be closely monitored 
for cardiac arrhythmia.
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treatments, of ?8 weeks duration were analyzed using a mixed treatment com-
parison. Bayesian hierarchical models were used to investigate three endpoints: 
lung function as assessed by forced expiratory volume in one second (FEV1) (n=28 
studies), annual moderate/severe exacerbation rate among patients with his-
tory of COPD exacerbations (n=15), and health status as assessed by St. George’s 
Respiratory Questionnaire (SGRQ) Total score (n=20). We compared ICS/LABA dos-
ages licensed in Europe, and report findings from comparisons of once-daily FF/VI 
92/22mcg with twice-daily fluticasone propionate (FP)/salmeterol (SAL) 500/50mcg 
and budesonide (BUD)/formoterol (FORM) 400/12mcg. Results: For FEV1, based 
on a 50mL delta, FF/VI demonstrated >99% probability of non-inferiority to FP/
SAL and BUD/FORM. On exacerbations, using a 10% event rate ratio delta, FF/VI 
demonstrated 73% probability of non-inferiority to FP/SAL and a 77% probability of 
non-inferiority to BUD/FORM. On SGRQ health status questionnaire scores, using 
a 2-unit delta, FF/VI demonstrated 99% probability of non-inferiority to FP/SAL 
and 98% probability of non-inferiority to BUD/FORM. Covariate effects of age and 
study duration were observed to impact on response for FEV1 and exacerbation 
rates, but not SGRQ. cOnclusiOns: Our findings suggest that once-daily FF/VI 
has comparable efficacy with established twice-daily combination therapies in 
COPD. Key limitations include weak/disconnected treatment networks and sus-
ceptibility of the results to study inclusion criteria.
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SChizoPhRenia SmokeRS – a SyStematiC RevieW
Wu I.H., Abughosh S.
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Objectives: Schizophrenia patients have noticeably higher smoking rates, higher 
nicotine dependence levels as well as lower smoking cessation rates compared to 
the general population. The objective of this study was to summarize the current 
evidence for efficacy of smoking cessation medications (nicotine replacement ther-
apy, Bupropion SR, or Varenicline) as treatments for nicotine dependence in patients 
with schizophrenia. MethOds: A similar Cochrane review and searching terms was 
published in 2010 but no study with Varenicline was available at that time because 
of its more recent FDA approval. Consequently, we first conducted a search for rand-
omized controlled trials of NRT, Bupropion SR, or Varenicline in adult smokers with 
schizophrenia that was published after 2010. Studies were searched with Medline 
(Ovid), PubMed (National Library of Medicine), Embase (Ovid), and PsycINFO (Ovid). 
Definition of abstinence was 8-14 weeks after the cessation treatment starts. Only 
studies with abstinence measured within this range were included. Studies were 
then combined together with the studies in Cocharne review with similar outcome 
definition. Results: Seven original studies were included in this review (1 for NRT, 
4 for Bupropion SR, and 2 for Varenicline). Majority of the medications achieved 
smoking cessation with a higher percentage as compared to placebo but most of 
the effects were not statistically significant. No significant changes in mental states 
were observed after the cessation treatments exposure. cOnclusiOns: Our review 
showed that most of the cessation medications slightly improved abstinence rates 
compared to placebo after 8 - 14 weeks of treatment, but this did not reach statisti-
cal significance. Only seven original studies were included due to limited available 
randomized controlled trials. Future studies could consider smoking reduction as 
an outcome as reaching abstinence might be difficult to achieve among schizo-
phrenia patients.
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Objectives: Patient-reported symptoms of chronic obstructive pulmonary dis-
ease (COPD) provide important supporting information about how patients feel 
and function in addition to objective measures of pulmonary function. This analy-
sis characterized the symptom response profiles of patients with moderate to 
severe COPD who initiated treatment with arformoterol or placebo. MethOds: 
Data for this post-hoc analysis came from a large, randomized, double-blind, 
safety trial of nebulized arformoterol 15µg BID (n= 420) or matched placebo 
(n= 421). Treatment with other non-long-acting beta agonists was permitted. 
This post-hoc analysis examined changes in the symptoms subscale of the St. 
George’s Respiratory Questionnaire (SGRQ). Growth Mixture Modeling (GMM) 
examined variability in individual responses over the 12-month study period 
and identified latent classes of differential responders conditional on treatment. 
Follow-up analyses characterized the baseline and treatment outcome profiles 
for the different latent classes. Results: The symptom score response profiles 
were best explained by two latent classes that were labeled “responders” and 
“non-responders.” Relative to “non-responders” (n= 259), “responders” (n= 571) 
were lower in age (63.0 vs. 65.1), more likely to smoke (55.5% vs. 44.0%), had 
more severe baseline symptoms score (75.4 vs. 46.0), and lower forced expira-
tory volume (liters) in one second (FEV1; 1.16 vs. 1.23). Responders had signifi-
cantly greater improvements in symptoms (-8.8 vs. -1.6), but not in FEV1 (0.05 
vs. 0.03). Among the responders, those treated with arformoterol had compara-
ble improvements in symptoms (-10.3 vs. -7.2, p> 0.05) and a similar number of 
exacerbations (0.55 vs. 0.69, p> 0.05), but significantly greater improvements in 
FEV1 (0.09 vs. 0.008, p= 0.03) and significantly fewer hospitalizations (0.13 vs. 0.24, 
p= 0.02). cOnclusiOns: In this analysis, symptom response profiles were best 
explained by two latent classes. Among the responders, arformoterol appeared 
to improved lung function and reduce hospitalizations. Arformoterol may be 
particularly effective among patients who are unable to quit smoking and have 
more severe symptoms.
PHY/MI. Musculoskeletal disorders were the most prevalent inflammation-related 
condition. Multinomial logistic regression revealed that women compared to 
men (AOR: 1.88; 95% CI:1.75, 2.01); older adults (55-64 years) compared to younger 
adults (18-24 years) had significantly higher likelihood (AOR: 6.14; 95% CI:5.05, 
7.04) of having IF_PHY/MI. Interestingly, African Americans, Hispanics and Asians 
had lower likelihood of having IF_PHY/MI compared to Whites. cOnclusiOns: 
High prevalence of inflammation-related multimorbidity among individuals with 
COPD warrant the need for clinical practice guidelines for evidence-based man-
agement.
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aSSoCiation betWeen aSthma-Related health CaRe utilization and 
tWo diffeRent tyPeS of aSthma tReatmentS among a CommeRCially 
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Objectives: To evaluate the relationship between asthma-related health care 
utilization with two different types of asthma treatments (inhaled Fluticasone 
Propionate (FP) and fixed dose combination of Fluticasone Propionate and 
Salmeterol (FPS)) among a commercially insured adolescent and adult popula-
tion. MethOds: This retrospective cohort study used propensity-score matching 
to identify patients in a large nationally representative administrative claims 
database. The sample consisted of patients aged 12 to 64 who had a new prescrip-
tion fill (index) for FP or FPS after asthma diagnosis (ICD-9-CM 493.XX) between 
2006 and 2012. Patients were continuously enrolled in a plan with pharmacy and 
medical coverage for at least 12 months before and after treatment initiation. 
Patients were excluded if they: (a) used FP or FPS within 90 days prior to index; (b) 
had a diagnosis of chronic obstructive pulmonary disease (ICD-9-CM 490.XX-492.
XX, 494.XX, 496.XX); or (c) used other asthma controller medications after index. 
Eligible patients were followed up to 12 months after initiation. A multivariate 
logistic regression model was used to observe the association between asthma-
related health care utilization in the two cohorts. Results: The study popula-
tion included 8,059 patients treated with FP (female= 57.0%, average age= 33.9 (± 
17.6), hospitalization rate= 1.4%, ED rate= 5.0%) and 8,059 patients treated with FPS 
(female= 57.5%, average age= 33.9 (± 17.4), hospitalization rate= 1.8%, ED rate= 5.5%). 
The multivariate logistic regression model revealed FPS users had no significant 
difference in likelihood of asthma-related hospitalizations (OR= 1.26; 95% CI 0.98-
1.62, p-value= 0.0667) or ED visits (OR= 1.13; 95% CI 0.98-1.3, p-value= 0.0884) com-
pared to FP users. cOnclusiOns: This large retrospective analysis found that 
users of FP versus FPS have statistically similar rates of asthma-related health care 
utilization at the 95% level. However, the large positive odds ratios, significant at 
the 90% level, indicate a need for additional research to investigate comparative 
effectiveness of the two therapies.
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tReatment effiCaCy of onCe-daily flutiCaSone fuRoate/vilanteRol 
(ff/vi) iS ComPaRable With tWiCe-daily Combination theRaPieS in 
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Svedsater H.1, Stynes G.1, Wex J.1, Frith L.1, Leather D.1, Castelnuovo E.1, Detry M.2, Berry S.2
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Objectives: To determine the relative treatment efficacy of FF/VI, a once-daily 
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination therapy, 
compared with corresponding dosages of established twice-daily ICS/LABA thera-
pies, in patients with asthma. MethOds: Following a systematic literature review, 
data from 31 parallel-group randomized controlled trials, consisting of 24 different 
treatments, of >8 weeks’ duration and in patients aged ?12 years were included 
in the mixed treatment comparison. Bayesian hierarchical models were used to 
investigate four endpoints: lung function (peak expiratory flow [PEF] (n=18 studies) 
and forced expiratory volume in one second [FEV1] (n=28)), annual exacerbation 
rates (n=6), and health status (Asthma Quality of Life Questionnaire [AQLQ]) (n=7). 
We compared ICS/LABA dosages licensed in Europe, and report findings from com-
parisons of once-daily FF/VI (92/22mcg and 184/22mcg) with twice-daily fluticasone 
propionate (FP)/salmeterol (SAL) (250/50mcg and 500/50mcg) and budesonide (BUD)/
formoterol (FORM) (400/12mcg and 800/24mcg). Results: On PEF, based on a 12L/
min delta, FF/VI 92/22mcg and 184/22mcg demonstrated ?94% and >99% probability 
of non-inferiority to corresponding doses of FP/SAL and BUD/FORM, respectively. On 
FEV1, based on a 100mL threshold, FF/VI demonstrated ?99% and ?98% probability of 
non-inferiority to FP/SAL and BUD/FORM. On exacerbations, using a 10% event rate 
ratio delta, FF/VI 92/22mcg demonstrated 74% and 82% probability of non-inferiority 
to corresponding doses of FP/SAL and BUD/FORM. On AQLQ, based on a score delta 
of 0.25, FF/VI 92/22mcg demonstrated >99% and 90% probability of non-inferiority 
to FP/SAL and BUD/FORM. There were insufficient data to assess non-inferiority of 
FF/VI 184/22mcg on exacerbations or AQLQ. cOnclusiOns:  Our findings suggest 
that once-daily FF/VI has comparable efficacy with established twice-daily combi-
nation therapies in asthma. Key limitations include weak/disconnected treatment 
networks and susceptibility of the results to study inclusion criteria.
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Objectives: To determine the relative treatment efficacy of FF/VI 92/22mcg, a 
once-daily inhaled corticosteroid (ICS)/long-acting beta2agonist (LABA) combi-
nation therapy, compared with established twice-daily ICS/LABA therapies, in 
patients with COPD. MethOds: Following a systematic literature review, data 
from 33 parallel-group randomized controlled trials, consisting of 26 different 
